期刊文献+

药源性显微镜结肠炎及其防治 被引量:7

Drug-induced microscopic colitis and its prevention and treatment
原文传递
导出
摘要 药源性显微镜结肠炎(DIMC)临床表现主要为慢性(持续性或间断性)非血性水样腹泻,内镜检查正常或大致正常,具有特殊的组织病理学表现。致病药物主要为非甾体抗炎药物、质子泵抑制剂及选择性5-羟色胺再摄取抑制剂等。发病机制主要与免疫异常有关。中老年、女性及联合用药为危险因素。处理措施为停用致病药物;症状轻者可使用洛哌丁胺,症状严重者可使用布地奈德;药物治疗无效者可手术治疗。过敏体质及自身免疫性疾病、过敏性疾病患者应慎用可导致DIMC的药物。 Clinical manifestations of drug-induced microscopic colitis (DIMC) are mainly chronic (continuous or intermittent) non-bloody watery diarrhea, a normal or almost normal endoscopic examination, and special histopathological characteristics. The drugs which cause DIMC mainly include nonsteroidal anti-inflammatory drugs, proton pump inhibitors, selective serotonin reuptake inhibitors, and others. The mechanism is associated with abnormal immunization. Risk factors for DIMC are middle-aged and elderly people, female, and combination therapy. The measures for treatment and prevention are as follows: the causative drugs should be discontinued; the patients with mild symptoms of DIMC could be treated with loperamide; the patients with severe symptoms of DIMC could be treated with budesonide; if drug treatment is ineffective, patients might undergo surgery; the drugs known to induce DIMC should be used with caution in patients with allergic diathesis, autoimmune disease, and allergic disease.
出处 《药物不良反应杂志》 2012年第5期290-293,共4页 Adverse Drug Reactions Journal
关键词 结肠炎 显微镜下 诊断 预防 治疗 colitis, microscopic diagnosis prevention treatment
  • 相关文献

参考文献5

二级参考文献153

  • 1Zsolt Barta,Gabriella Mekkel,István Csíp(o|"),László Tóth,Szabolcs Szakáll,Gábor G.Szabó,Gyula Bakó,Gyula Szegedi,Margit Zeher.Microscopic colitis: A retrospective study of clinical presentation in 53 patients[J].World Journal of Gastroenterology,2005,11(9):1351-1355. 被引量:3
  • 2Ahmed Madisch,Birgit Bethke,Manfred Stolte,Stephan Miehlke.Is there an association of microscopic colitis and irritable bowel syndrome-A subgroup analysis of placebo-controlled trials[J].World Journal of Gastroenterology,2005,11(41):6409-6409. 被引量:4
  • 3[1]Thomas PD,Forbes A,Green J,Howdle P,Long R,Playford R,Sheridan M,Stevens R,Valori R,Walters J,Addison GM,Hill P,Brydon G.Guidelines for the investigation of chronic diarrhoea,2nd edition.Gut 2003;52 Suppl 5:v1-v15
  • 4[2]Pardi DS.Microscopic colitis:an update.Inflamm Bowel Dis 2004;10:860-870
  • 5[3]Lindstr(o)m CG.'Collagenous colitis' with watery diarrhoea-a new entity? Pathol Eur 1976;11:87-89
  • 6[4]Lazenby AJ,Yardley JH,Giardiello FM,Jessurun J,Bayless TM.Lymphocytic ("microscopic") colitis:a comparative histopathologic study with particular reference to collagenous colitis.Hum Patho11989;20:18-28
  • 7[5]Olesen M,Eriksson S,Bohr J,J?rnerot G,Tysk C.Microscopic colitis:a common diarrhoeal disease.An epidemiological study in Orebro,Sweden,1993-1998.Gut 2004;53:346-350
  • 8[6]Pardi DS,Loftus EV Jr,Smyrk TC,Kammer PP,Tremaine WJ,Schleck CD,Harmsen WS,Zinsmeister AR,Melton LJ 3rd,Sandborn WJ.The epidemiology of microscopic colitis:a population based study in Olmsted County,Minnesota.Gut 2007;56:504-508
  • 9[7]Rubio-Tapia A,Martínez-Salgado J,Garcia-Leiva J,Martínez-Bertttez B,Uribe M.Microscopic colitides:a single center experience in Mexico.Int J Colorectal Dis 2007;22:1031-1036
  • 10[8]Fekih M,Ben Hriz F,Sassi A,Matri S,Filali A,Boubaker J.[Microscopic colitis.A 20 cases series] Tunis Med 2006;84:403-406

共引文献9

同被引文献100

  • 1朱珠,蔡乐.质子泵抑制剂的安全性与合理应用[J].药物不良反应杂志,2005,7(2):81-90. 被引量:56
  • 2Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19:25-35.
  • 3Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16:2323-2330.
  • 4L?drup AB, Reimer C, Bytzer P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scand J Gastroenterol. 2013;48:515-522.
  • 5Teixeira MZ. Rebound acid hypersecretion after withdrawal of gastric acid suppressing drugs: new evidence of similitude. Homeopathy. 2011;100:148-156.
  • 6Barrett TD, Lagaud G, Wagaman P, Freedman JM, Yan W, Andries L, Rizzolio MC, Morton MF, Shankley NP. The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat. Br J Pharmacol. 2012;166:1684-1693.
  • 7Niv Y. Gradual cessation of proton pump inhibitor (PPI) treatment may prevent rebound acid secretion, measured by the alkaline tide method, in dyspepsia and reflux patients. Med Hypotheses. 2011;77:451-452.
  • 8Famularo G, Gasbarrone L, Minisola G. Hypomagnesemia and proton-pump inhibitors. Expert Opin Drug Saf. 2013;12:709-716.
  • 9Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Srivali N, Edmonds PJ, Ungprasert P, O'Corragain OA, Korpaisarn S, Erickson SB. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37:1237-1241.
  • 10Tamura T, Sakaeda T, Kadoyama K, Okuno Y. Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2012;9:322-326.

引证文献7

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部